What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• After demand for GLP‑1 medicines (semaglutide, tirzepatide and others) surged in 2023–2024, many compounding pharmacies began making and selling compounded “GLP‑1” injections/solutions from bulk peptide ingredients. The FDA concluded that much of that activity looked like making unapproved versions of approved drugs and posed safety risks, and it issued safety communications and warning letters, worked with state regulators, and stepped up enforcement.
• That didn’t mean all compounding stopped or became illegal. Legally operating entities are: (A) manufacturers and retail pharmacies supplying FDA‑approved GLP‑1 products (e.g., Novo Nordisk — Ozempic, Wegovy; Eli Lilly — Mounjaro, Zepbound; others), and (B) compounding pharmacies and outsourcing facilities that follow the law (see details below).

What the FDA’s actions were and why

• FDA concerns: compounded GLP‑1 products often used bulk active pharmaceutical ingredients (APIs) not authorized for compounding, had variable or unknown purity/dosing, lacked manufacturing controls, and were sometimes marketed like finished drugs. That raises safety (contamination, wrong dose), efficacy, and diversion/quality issues.
• Enforcement steps: FDA issued public safety communications warning clinicians and consumers, published warning letters to specific firms, and increased inspections and referrals to state boards of pharmacy and law enforcement when appropriate. FDA has emphasized using FDA‑approved GLP‑1 products whenever possible.

Who can legally supply GLP‑1s now

• FDA‑approved manufacturers/retail pharmacies: The safest/legal route is a prescription for an FDA‑approved GLP‑1 product filled by a licensed retail or specialty pharmacy (examples: Novo Nordisk — Ozempic/Wegovy; Eli Lilly — Mounjaro/Zepbound; Rybelsus for oral semaglutide, etc.). Those are approved, labeled products with known manufacturing controls.
• 503A compounding pharmacies (traditional): May compound medicines only in response to a patient‑specific prescription and must follow state pharmacy law. Many GLP‑1 peptides are not on the FDA’s list of bulk substances that can be routinely used for 503A compounding; compounding from bulk APIs without a patient‑specific need often draws FDA/state scrutiny.
• 503B outsourcing facilities: Can compound larger quantities without a patient‑specific prescription but must comply with federal current good manufacturing practices (cGMP) and be subject to FDA inspection. A 503B may be able to operate legally only if it uses permitted sources and follows FDA rules.
• State boards of pharmacy: They regulate many compounding pharmacies and have authority to discipline or close facilities that are not complying with state law and standards.

How to tell if a compounded GLP‑1 is being provided legally and safely

• Prefer FDA‑approved products when possible.
• If you’re offered a compounded product, ask the prescriber/pharmacy for:
  • The name and license/registration (503A vs 503B) of the pharmacy.
  • A current certificate of analysis (COA) and batch testing results proving identity, purity, and sterility.
  • Evidence the product was made for a patient‑specific prescription (for 503A) or that the 503B is inspected and compliant with cGMP.
  • Proof the active ingredient source is legally permitted.
• Check the FDA website for posted warning letters and safety communications and your state board of pharmacy for any disciplinary actions against the pharmacy.

Practical recommendation

• If you need a GLP‑1 for diabetes or weight management, get it prescribed from a clinician and filled as an FDA‑approved product through a reputable retail or specialty pharmacy (Novo Nordisk, Eli Lilly products listed above). That avoids the legal/quality uncertainty that prompted FDA action against many compounders.
• If you already have a compounded GLP‑1 or are considering one, ask the questions above and talk to your prescriber about switching to an FDA‑approved option unless there’s a documented, patient‑specific medical reason compounding is necessary.

If you want, tell me the name of a particular pharmacy or product you’ve seen and I can check what kinds of public FDA or state actions were taken (or point you to the specific FDA safety communication and the relevant 503A/503B guidance).